Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LENS: Fenofibrate to Prevent Progression of Non‑Proliferative Diabetic Retinopathy
2016-002656-24Phase 4Unknown
- Sponsor
- University of Oxford
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in diabetic retinopathy (DR), diabetic macular edema (DME), diabetes mellitus type 1 (T1D) and 1 more comparing Fenofibrate (Lipantil Supra) with Placebo (2 arms). Primary endpoint: Composite primary outcome of clinically significant diabetic retinopathy or ocular intervention. Status: unknown.
02
Drugs
fenofibrate
03
Conditions
diabetic retinopathy (DR)diabetic macular edema (DME)diabetes mellitus type 1 (T1D)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2016-002656-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002656-24.